Drugs / X-82
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02146222 | Sep 2014 → Dec 2016 | cancer of unknown primary site | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01674569 | Oct 2012 → Feb 2015 | wet macular degeneration | Tyrogenex | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02348359 | Mar 2015 → Dec 2017 | age related macular degeneration 10, wet macular degeneration | Tyrogenex | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | X-82 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02146222 ↗ |
| Action | Inhibit | “VEGFR/PDGFR dual kinase inhibitor X-82 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT02146222 ↗ |
| Modality | Small molecule | “X-82 is an oral tyrosine kinase inhibitor active against vascular endothelial growth factor (VEGF) and platelet-derived growth factor.” PMID 28570723 ↗ Jul 2017 |
| Route | Oral | “Participants received oral X-82 for 24 weeks” PMID 28570723 ↗ Jul 2017 |